ArticleFrontiers in pharmacology2026
Nomogram-based prediction of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a retrospective study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asparaginase is a crucial drug in acute lymphoblastic leukemia (ALL) treatment, but its use is frequently complicated by asparaginase-associated pancreatitis (AAP). Although several risk factors for AAP have been identified, no comprehensive predictive model is currently available to assess individual patient risk. We aimed to develop and validate a nomogram for AAP risk in children with ALL. Methods: We conducted a retrospective study of 352 children with ALL diagnosed at Hebei Children's Hospital from January 2020 to June 2025, all treated according to the Chinese Children's Leukemia Group Acute Lymphoblastic Leukemia 2018 (CCLG-ALL-2018) protocol. Patients were divided into AAP and non-AAP groups based on the 2012 Atlanta diagnostic criteria for pancreatitis. Clinical data and laboratory parameters were systematically collected. Least absolute shrinkage and selection operator (LASSO) regression was used for variable selection, followed by multivariate logistic regression to construct the prediction model. Model performance was assessed using the receiver operating characteristic (ROC) curve analysis, calibration curves, and decision curve analysis (DCA). Results: Among the 352 patients (median age 5.0 years; 56.53% boys), 36 patients (10.23%) developed AAP. Six independent risk factors were identified: history of AAP (odds ratio [OR] = 13.20, Conclusion: A nomogram incorporating six available clinical and laboratory parameters was successfully developed and validated to predict AAP risk in children with ALL. The model demonstrated excellent predictive performance and clinical applicability, providing a valuable tool for early identification of high-risk AAP patients and guiding individualized preventive strategies to optimize treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.